Co-supplementation of healthy women with fish oil and evening primrose oil increases plasma docosahexaenoic acid, gamma-linolenic acid and dihomo-gamma-linolenic acid levels without reducing arachidonic acid concentrations by Geppert, Julia et al.
Co-supplementation of healthy women with fish oil and evening primrose oil
increases plasma docosahexaenoic acid, g-linolenic acid and dihomo-g-
linolenic acid levels without reducing arachidonic acid concentrations
Julia Geppert1, Hans Demmelmair1, Gerard Hornstra2 and Berthold Koletzko1*
1Division of Metabolic Diseases and Nutrition, Dr von Hauner Children’s Hospital, Ludwig Maximilians University of Munich,
Germany
2NUTRIM, University of Maastricht, The Netherlands
(Received 31 January 2007 – Revised 27 June 2007 – Accepted 28 June 2007)
Fish oil supplementation during pregnancy not only improves maternal and neonatal DHA status, but often reduces g-linolenic acid (GLA),
dihomo-GLA (DGLA), and arachidonic acid (ARA) levels also, which may compromise foetal and infant development. The present study inves-
tigated the effects of a fish oil/evening primrose oil (FSO/EPO) blend (456mg DHA/d and 353mg GLA/d) compared to a placebo (mixture of
habitual dietary fatty acids) on the plasma fatty acid (FA) composition in two groups of twenty non-pregnant women using a randomised,
double-blind, placebo-controlled parallel design. FA were quantified in plasma total lipids, phospholipids, cholesterol esters, and TAG at
weeks 0, 4, 6 and 8. After 8 weeks of intervention, percentage changes from baseline values of plasma total lipid FA were significantly different
between FSO/EPO and placebo for GLA (þ49·9% v. þ2·1%, means), DGLA (þ13·8% v. þ0·7%) and DHA (þ59·6% v. þ5·5%), while there
was no significant difference for ARA (22·2% v. 25·9%). FA changes were largely comparable between plasma lipid fractions. In both groups
three subjects reported mild adverse effects. As compared with placebo, FSO/EPO supplementation did not result in any physiologically relevant
changes of safety parameters (blood cell count, liver enzymes). In women of childbearing age the tested FSO/EPO blend was well tolerated and
appears safe. It increases plasma GLA, DGLA, and DHA levels without impairing ARA status. These data provide a basis for testing this FSO/
EPO blend in pregnant women for its effects on maternal and neonatal FA status and infant development.
Docosahexaenoic acid: g-Linolenic acid: Fatty acid composition: Randomised controlled trial
Essential fatty acids (EFA) and their longer-chain polyunsatu-
rated derivatives (LCPUFA) are indispensable for human
development and optimum health. DHA (22: 6n-3) and arachi-
donic acid (ARA, 20 : 4n-6) are considered the most important
functional LCPUFA. Although they can be synthesised in the
body from a-linolenic acid and linoleic acid, respectively, this
synthesis capacity is restricted by the low activity of the rate-
limiting enzyme D6-desaturase. Endogenous formation of
DHA and ARA is thought to be insufficient under certain cir-
cumstances1 and additional dietary intake is needed to cover
metabolic requirements. This applies particularly under con-
ditions of increased EFA and LCPUFA requirements, such
as pregnancy, lactation and early human development.
DHA and ARA are found in high concentrations in struc-
tural lipids of the central nervous system and have been
shown to be important for brain development and function2–4.
Adequate accretion of both DHA and ARA in the brain and
retina is particularly important during the rapid brain
growth, which takes place in the perinatal period4. It is now
generally accepted that postnatal DHA administration pro-
motes, at least temporarily, cognitive and visual development
of infants born preterm5–9. Developmental benefit of postnatal
DHA supplementation has been observed in term infants also,
but the results are less consistent10,11.
Additionally, lactating mothers may benefit from postnatal
LCPUFA supplementation themselves, since a low maternal
DHA status has been suggested to increase the risk of post-
natal depression12. This hypothesis is supported by recent find-
ings that a higher DHA status at delivery13 and a better
recovery of the maternal DHA status after delivery14 are
associated with fewer depressive symptoms during the post-
natal period. In a longitudinal study it appeared that postnatal
depression is often preceded by depression around the thirty-
second week of pregnancy15, which may also be DHA-related.
Therefore, a higher DHA status during early pregnancy may
be beneficial in the prevention of pre- and postnatal
depression.
Dietary supplementation with DHA not only improves
the DHA status, but also reduces g-linolenic acid (GLA,
18 : 3n-6), dihomo-GLA (DGLA, 20 : 3n-6) and ARA concen-
trations in plasma and erythrocytes16–23. ARA is the second-
most abundant LCPUFA in the brain, and ARA-derived
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eicosanoids are important functional mediators24. ARA is
involved in cell signalling25 and is one of the major fatty
acid moieties of anandamides, which are ligands of the canna-
binoid receptor in the brain26. However, whereas DHA has
been investigated in several prospective trials, the possible rel-
evance of ARA for development and function has yet to be
confirmed in clinical settings. There is limited evidence for
a beneficial effect of ARA on brain development and function,
when it is given in combination with DHA to term infants27.
But cerebral ARA may be involved in neuromental disorders
like schizophrenia28. Whether or not the ARA reduction
associated with DHA supplementation interferes with DHA-
induced functional benefits is not known. Because of this
risk, the supplementation of mothers or infants with the aim
to improve the DHA status should not compromise maternal
and neonatal ARA status.
A lower maternal GLA and DGLA status following DHA
supplementation during pregnancy can be expected to
decrease the neonatal status of these fatty acids, as the
maternal and neonatal EFA–LCPUFA status is positively cor-
related29. A low intrauterine availability of (D)GLA could pre-
dispose individuals to increased risk of obesity, insulin
resistance and hypertriacylglycerolaemia in later life, since
these conditions at 7 years of age have been shown to be
inversely related to the (D)GLA status at birth30. In addition,
a significant, positive relationship has been observed between
the DGLA status of the neonate and its birth weight31. A lim-
ited availability of nutrients early in life (resulting in reduced
birth weight) could lead to the development of certain chronic
diseases in later life according to the foetal origins of adult
diseases hypothesis32,33. In addition by activating PPAR
GLA may be essential in the transcription of genes involved
in glucose and lipid homeostasis34,35 and GLA is thought to
reduce the risk of atopy36,37. Therefore, any supplementation
of mothers or infants intended to improve their DHA status
should not compromise, but rather improve maternal and neo-
natal GLA and DGLA status.
A simple way to avoid the decrease of maternal and
neonatal GLA, DGLA and ARA levels with DHA supplemen-
tation may be the addition of GLA to the supplement. Previous
studies observed increased plasma concentrations of DGLA as
well as (in most studies) ARA and GLA levels after GLA sup-
plementation38–43. The objective of this study was to investi-
gate the effects of a fish oil (FSO)/evening primrose oil (EPO)
blend on plasma fatty acid composition and its tolerance and
safety in healthy, non-pregnant women. We hypothesised
that the co-supplementation of DHA and GLA would increase
plasma DHA, GLA, and DGLA levels without impairing the
ARA status.
Subjects and methods
Subjects and study design
Forty apparently healthy women aged from 19 to 36 years
were recruited in the Munich area via posters displayed on
the university campus, and through personal contacts.
Inclusion criteria were female gender, age between 18 and
40 years and BMI between 18 and 25 kg/m2. Exclusion criteria
were hypertension (defined as a systolic blood pressure
.140mm Hg or a diastolic blood pressure .90mmHg44),
diagnosed metabolic, cardiovascular, renal or neurological dis-
eases, long-term use of medication (contraceptives excluded),
use of EFA or LCPUFA supplements, drug abuse, smoking of
.5 cigarettes per day, consumption of .7 glasses alcohol per
week, consumption of fish more than twice weekly, pregnancy
or lactation, vegetarian lifestyle during the last 3 months,
and participation in any other study. Vegetarians were
excluded because they have a different background diet with
low intakes of ARA, EPA and DHA and also often have
different life-styles as compared with the majority of the
population. These differences would likely have an impact
on the EFA status and, consequently, increase the variability
of the results. Ethical approval for the study was obtained
from the Bavarian Board of Physicians. Subjects gave their
written informed consent and received financial compensation
for their participation.
The study was conducted between June and August 2005 as
a randomised, double-blind, placebo-controlled intervention
study with two parallel groups. All volunteers completed a
health and lifestyle questionnaire before entering the study.
The subjects consumed 3·4 g daily of either a FSO/EPO
blend (providing 456mg DHA, 73mg EPA, 14mg ARA and
353mg GLA as TAG per day) or the same amount of a pla-
cebo (blend of palm oil, rapeseed oil, and sunflower seed
oil) for 8 weeks. The doses of DHA and GLA were chosen
so as to meet the recommended minimum intake of 200mg
DHA/d for pregnant and lactating women45, to lead to measur-
able increases of the corresponding plasma levels, the highest
GLA amount possible (for optimum efficiency to increase the
(D)GLA contents and to prevent a FSO-induced ARA
reduction), and to keep the total number of capsules of avail-
able preparations (mixtures of EPO and FSO) to be taken
within practicable limits (six capsules per day).
The subjects were randomly assigned to one of the interven-
tion groups. There were no significant differences in subject
characteristics between the two intervention groups at study
entry (Table 1).
Fasted blood samples were collected at weeks 0 (baseline),
4, 6 and 8. Body weight, blood pressure, and heart rate were
measured at study entry and after 8 weeks of intervention;
height was measured at baseline only. During the intervention,
the subjects noted side effects, signs of illness, intake of medi-
cation and the number of capsules they had failed to take.





Mean SD Mean SD P *
Age (years) 24·6 4·2 24·8 2·9 0·863
BMI (kg/m2) 21·8 1·9 21·9 2·0 0·823
Blood pressure (mm Hg)
Systolic 118 13 119 11 0·743
Diastolic 74 7 73 8 0·741
Heart rate (beats/min) 76 13 74 14 0·767
Non-smokers (n) 18 14 0·235
Use of oral contraceptives (n) 12 12 1·000
FSO/EPO, fish oil and evening primrose oil blend.
* The between-group differences at baseline were analysed using Student’s
unpaired t test or X 2 test as appropriate.
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Compliance was assessed by counting the returned capsules
and expressing the number as a percentage of the prescribed
number of capsules. To check the success of blinding, the sub-
jects were asked at the end of the study to guess their group
assignment.
Study oils
Each FSO/EPO capsule (mean filling weight 572·2mg)
consisted of 76·5% EPO (EFAMOL Ltd, Brackenholme,
Selby, North Yorkshire, UK) and 22·5% FSO (Incromega
DHA 500 TG SR, Croda Chemicals Europe Ltd, Cowick
Hall, East Yorkshire, UK). Matching placebo capsules
(mean filling weight 567·2mg) contained a blend of palm
oil (59·4%), rapeseed oil (19·8%), and sunflower seed oil
(19·8%) with a fatty acid composition comparable to the
habitual fatty acid composition of a standard Western diet.
Because of the non-translucent encapsulation, FSO/EPO and
placebo capsules were visually indistinguishable. All capsules
contained 1% of synthetic vitamin E acetate for stabilisation
of the oils. Table 2 gives the fatty acid composition of the
study oils as determined in our laboratory. The volunteers
were asked to take 2 £ 3 capsules or 3 £ 2 capsules daily
together with the meals (a total of six capsules per day).
The capsules were stored either refrigerated or at room tem-
perature in a dry, dark place.
Measurements, blood sampling and storage
All anthropometric measurements followed standardised pro-
cedures. Height without shoes was measured to the nearest
5mm and body weight without shoes and outdoor clothing
to the nearest 100 g using a digital scale. A lump sum of
1 kg was subtracted for the weight of the remaining clothes.
Blood pressure and heart rate were determined in sitting pos-
ition using a digital sphygmomanometer.
Venous blood samples were collected from the antecubital
vein into an EDTA-containing tube (Sarstedt, Nümbrecht,
Germany) from sitting or lying subjects. The blood was centri-
fuged at 48C (1500 g for 5min) within 2 h. Aliquots of the
plasma were transferred into two plastic storage vials, which
were tightly closed under a stream of N2, and stored at
2808C for 4 months maximally before the analysis of total
lipid (TL), phospholipid (PL), TAG and cholesterol ester
(CE) fatty acids. At baseline and after 8 weeks of supplemen-
tation, two additional blood samples were collected into a
lithium heparin tube and into an EDTA tube (both Sarstedt,
Nümbrecht, Germany) for the measurement of liver enzyme
activities and a full blood cell count, respectively. All samples
of a particular subject (weeks 0, 4, 6, and 8) were analysed in
the same analytical run. Full blood count and liver enzyme
assays were done on the day of blood drawing using the rou-
tine methods of the clinical chemistry laboratories of the Uni-
versity of Munich hospital.
Analytical methods
Fatty acid methyl esters (FAME) from 30ml study oil TAG
were obtained by reacting the oils with 2ml 1·5 M methanolic
HCl and 0·5ml hexane at 908C for 60min in closed glass
tubes. After adding 2ml distilled water and 2ml hexane
with butylated hydroxytoluene (2 g/l), the samples were vor-
texed and centrifuged. The upper hexane phase containing
the FAME was analysed by capillary GLC (Hewlett-Packard
5890 Series II gas chromatograph, equipped with a
60m £ 0·32mm BPX-70 column; SGE, Weiterstadt,
Germany). Flame ionisation detector signals were evaluated
with the software EZ-Chrom Elite version 2.61 (Scientific
Software, Pleasanton, USA). FAME peaks were identified by
comparison with commercial standards (Nu-Check-Prep, Ely-
sian, MN, USA). The instrument was calibrated regularly by
using a quantitative standards mixture (GLC-85, Nu-Chek,
Elysian, MN, USA) to update the response factors. Area per-
centages of all fatty acids determined (14–24 C-atoms) cor-
rected with response factors were calculated.
For the quantification of fatty acids in plasma TL and lipid
fractions, defined concentrations of dipentadecanoyl phospha-
tidylcholine, pentadecanoic acid, tripentadecanoin, and choles-
teryl pentadecanoic acid (Sigma, Deisenhofen, Germany) were
used as internal standards. Plasma lipids were extracted
according to a modified Folch method46 using chloroform–
methanol (2 : 1, v/v, containing 50mg butylated hydroxyto-
luene/l). TLC with heptane–diisopropyl ether–acetic acid
(60 : 40 : 3, by vol.) as mobile phase47 was used for separating
PL, free cholesterol, NEFA, TAG and CE. For the analysis of
plasma TL, TL extracts were directly transferred into glass
tubes and taken to dryness under N2.
FAME from individual fractions and from TL were
obtained by reaction with 3M methanolic HCl at 858C for
45min. Derivatives were extracted into hexane, dried under
N2 and stored in 50 ml hexane (2 g/l butylated hydroxytoluene)
until analysis at 2808C. Analysis of FAME was performed by
capillary GLC as described for the study oils. Absolute fatty
acid concentration (mg/l) of all identified fatty acids with
14–24 C atoms was determined via comparison with the
peak area of the internal standard (15 : 0) and correction
with the accordant response factor. Additionally, fatty acid
weight percentages (wt% (g/100 g total fatty acids)) were cal-
culated. The method used for fatty acid analysis in plasma TL
and lipid fractions showed a good reproducibility: intra-assay
CV (n 8) of all presented fatty acids were below 3% and inter-
assay CV below 5% (n 10 or 11).
Full blood cell counts were performed in EDTA blood on an
automatic analyser (Coulter Micro Diff II, Beckmann Coulter,
Table 2. Major fatty acids of FSO/EPO and placebo oils (g/100 g total
fatty acids)
FSO/EPO (n 4)* Placebo (n 4)*
Mean SD Mean SD
16 : 0 4·93 0·03 28·46 0·03
18 : 0 1·84 0·01 3·63 0·01
18 : 1 5·98 0·06 42·01 0·07
18 : 2n-6 56·64 0·04 21·37 0·20
18 : 3n-6 10·28 0·03 ND
20 : 4n-6 0·41 0·00 ND
18 : 3n-3 0·17 0·01 2·06 0·03
20 : 5n-3 2·13 0·02 ND
22 : 6n-3 13·28 0·06 ND
FSO/EPO, fish oil and evening primrose oil blend; ND, not detected.
* As determined in our laboratory.
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Krefeld, Germany). g-Glutamyl transpeptidase, alanine amino-
transferase, aspartate aminotransferase, and cholinesterase were
measured from lithium heparin plasma with an automated
sample processor (Roche/Hitachi 912, Roche Diagnostics
GmbH, Mannheim, Germany) with the appropriate reagent
systems.
Statistical analyses
Statistical evaluation was carried out with SPSS 12·0 for Win-
dows (SPSS Inc., Chicago, USA). Data were checked for nor-
mality by visual inspection and by Kolmogorov–Smirnov test
(with Lilliefors correction).
For volunteer characteristics and safety parameters at base-
line, as well as for the impact of treatment on their absolute
changes (week 8 minus week 0), differences between groups
were evaluated using either Student’s unpaired t test (for nor-
mally distributed variables) or the Mann–Whitney U test (for
variables not normally distributed). Exact significances were
calculated for all nonparametric tests.
Fatty acid concentrations were transformed for statistical
analyses in case of non-normality to obtain a normal distri-
bution. The overall effect of treatment on fatty acid compo-
sition was determined using the General Linear Model for
repeated measures corrected for fatty acid concentrations at
baseline (week 0). The between-subjects factor had two
levels (‘placebo’ v. ‘FSO/EPO’), whereas the within-subjects
factor ‘time’ had three levels (weeks 4, 6, and 8). Levene’s
test was used to check equality of variances of studentised
residuals. In case transformation did not result in normally dis-
tributed data, the General Linear Model procedure was still
adopted, if studentised residuals showed a normal distribution.
The effects of treatment were further described by compar-
ing data from weeks 4, 6, and 8 with baseline data within each
group using Student’s paired t test or Wilcoxon nonparametric
test both with the Bonferroni–Holm correction48 for multiple
comparisons. Additionally, relative fatty acid changes from
baseline values after 8 weeks (%) were compared between
treatment groups by Student’s unpaired t test for normally dis-
tributed variables or the Mann–Whitney U test for variables
not normally distributed.
Correlations between parameters were estimated by comput-
ing the Spearman r correlation coefficient. For bivariate tabular
analysis the x 2 test (exact calculation) was used. In cases of
expected values smaller than 5, a Fisher exact test was used
instead. Unless otherwise noted, results are given as mean
values with corresponding standard errors. Values of P,0·05
were considered significant unless otherwise stated.
Results
One subject from the FSO/EPO group dropped out during the
first 4 weeks of the intervention period because she contracted
abdominal influenza and could not take the capsules for more
than 7 d. Thus, thirty-nine subjects (97·5%) were included in
the statistical analysis.
Compliance, side effects and success of blinding
Compliance as judged by capsule count (median) was 99%
(interquartile range 98–100%) for the FSO/EPO group and
99% (interquartile range 97–99%) for the placebo group
with no significant between-group difference. In both the
active as well as the placebo group, three subjects reported
mild adverse effects including gastrointestinal upsets (indiges-
tion, belching), minor skin reactions (pimples) and slightly
increased bleeding tendency. Side effects were evenly distrib-
uted between FSO/EPO and placebo groups (P.0·05). Group
assignment was guessed correctly in the FSO/EPO group by
63% and in the placebo group by 50% of the subjects with
no significant group difference (P¼0·523).
BMI, blood pressure and heart rate
Body weight, BMI, blood pressure and heart rate did not differ
between FSO/EPO and placebo groups at week 0 and absolute
changes frombaseline after 8weeks of interventionwere not sig-
nificantly different between the two groups (data not shown).
Full blood cell count and liver enzymes
All observed changes in haematology and liver enzymes were
minor and within the normal ranges (data not shown). Inci-
dence of liver enzymes and haematological parameters
beyond the laboratory’s reference ranges were comparable
between FSO/EPO and placebo groups, both at baseline as
well as at week 8. Basal values and supplementation effects
of plasma fatty acids were not different between subjects
whose laboratory parameters were within or outside the refer-
ence range, respectively (data not shown).
Fatty acid composition of plasma total lipids and lipid
fractions
For plasma TL and for all three plasma lipid fractions, the Gen-
eral LinearModel for repeatedmeasures (weeks 4, 6, and 8) cor-
rected for fatty acid percentages at baseline (week 0)
demonstrated significant increasing effects of FSO/EPO treat-
ment compared to placebo on GLA, DGLA, ARA (in plasma
TAG only), and DHA. No significant effects of treatment were
observed on ARA levels in plasma TL, PL, and CE (Table 3–6).
Furthermore, compared to placebo, the General Linear
Model procedure revealed significant increasing effects of
FSO/EPO treatment on EPA levels and significant decreasing
effects on concentrations of Mead acid, n-6 and n-3 docosa-
pentaenoic acids, a-linolenic acid, and the sum of MUFA in
some or all investigated lipid domains (data not shown).
Relative changes in fatty acid composition after eight weeks of
intervention
After 8 weeks of intervention, relative increases (as a percen-
tage of baseline values) were significantly greater with FSO/
EPO than with placebo treatment for GLA, DGLA and
DHA in plasma TL and lipid fractions (Fig. 1). There were
no between-group differences in relative ARA changes for
plasma TL, PL and CE, but a significantly greater ARA
increase occurred in plasma TAG with FSO/EPO treatment
compared to placebo. In the FSO/EPO group, mean GLA
change from baseline was þ49·9% in plasma TL and
þ42·8%, þ 47·2% and þ47·3% in plasma PL, CE and
TAG, respectively. DGLA levels increased by þ13·8% in
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plasma TL and by þ13·5%, þ 18·0% and þ27·5% in the
respective lipid fractions. Relative ARA changes from base-
line with FSO/EPO treatment accounted for 22·2% in
plasma TL, 25·4% in PL, þ2·2% in CE and þ13·7% in
TAG. DHA changes from baseline values in plasma TL, PL,
CE, and TAG were þ59·6%, þ 53·7%, þ 60·7% and
þ145·0%, respectively.
Correlations between relative fatty acid concentrations
Spearman r correlation coefficients were computed between
plasma TL and lipid fraction fatty acid levels (wt%) for GLA,
DGLA, ARA, and DHA in all subjects at respective time
points (n 39–40). Because of multiple comparisons, values of
P,0·001 are considered significant, while values of P,0·01
are considered a strong trend. Consistently significant positive
correlations or a strong positive trend (P¼0·002 between ARA
in TL and TAG at week 4) were observed between plasma TL
and lipid fraction fatty acid levels. Correlation coefficients
between TL and CE were .0·85 for all presented fatty acids.
Furthermore, correlations between TL and PL were also
.0·73 for all presented fatty acids. Correlation coefficients
between TL and TAG fatty acids were .0·66 for GLA,
DGLA, and DHA and.0·47 for ARA levels (data not shown).
Table 4. Fatty acid composition of plasma cholesterol esters (g/100 g total fatty acids)
FSO/EPO (n 19) Placebo (n 20)
Overall effect of treatment
Fatty acid Time (week) Mean SEM Mean SEM P *
18 : 3n-6† 0 0·913 0·045 0·893 0·080
4 1·286‡ 0·076 0·812 0·051
,0·001
6 1·114‡ 0·063 0·877 0·070
8 1·277‡ 0·061 0·810 0·058
20 : 3n-6† 0 0·873 0·034 0·770 0·039
4 0·992‡ 0·049 0·785 0·042
,0·001
6 1·028‡ 0·055 0·779 0·040
8 1·034‡ 0·051 0·757 0·037
20 : 4n-6† 0 6·84 0·34 7·06 0·25
4 6·99 0·34 7·07 0·26
0·152
6 7·21 0·44 6·83 0·25
8 6·98 0·42 6·70 0·21
22 : 6n-3 0 0·620 0·022 0·581 0·036
4 0·938‡ 0·041 0·616 0·042
,0·001
6 1·016‡ 0·044 0·614 0·041
8 0·979‡ 0·041 0·604 0·044
FSO/EPO, fish oil and evening primrose oil blend.
* The overall effect of treatment on fatty acid composition was determined using the General Linear Model for repeated
measures corrected for fatty acid concentrations at baseline.
† Data were transformed before statistical analyses.
‡ Significantly different from baseline values (Bonferroni-Holm adjusted significances48).
Table 3. Fatty acid composition of plasma total lipids (g/100 g total fatty acids)
FSO/EPO (n 19) Placebo (n 20)
Overall effect of treatment
Fatty acid Time (week) Mean SEM Mean SEM P *
18 : 3n-6† 0 0·360 0·018 0·369 0·034
4 0·532‡ 0·029 0·322 0·021
,0·001
6 0·462‡ 0·025 0·360 0·028
8 0·516‡ 0·026 0·329 0·029
20 : 3n-6 0 2·00 0·07 1·76 0·08
4 2·25‡ 0·11 1·76 0·08
0·002
6 2·20‡ 0·09 1·78 0·08
8 2·27‡ 0·10 1·73 0·08
20 : 4n-6† 0 6·70 0·31 7·03 0·23
4 6·65 0·29 6·89 0·22
0·451
6 6·80 0·39 6·67‡ 0·25
8 6·52 0·35 6·57‡ 0·18
22 : 6n-3 0 2·04 0·10 1·87 0·09
4 3·12‡ 0·11 1·98 0·13
,0·001
6 3·25‡ 0·11 1·92 0·11
8 3·14‡ 0·10 1·97 0·14
FSO/EPO, fish oil and evening primrose oil blend.
* The overall effect of treatment on fatty acid composition was determined using the General Linear Model for repeated
measures corrected for fatty acid concentrations at baseline.
† Data were transformed before statistical analyses.
‡ Significantly different from baseline values (Bonferroni-Holm adjusted significances48).
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Correlations between relative fatty acid changes from baseline
Spearman r correlation coefficients were computed between
plasma TL and lipid fraction fatty acid changes (% of basal
value) for GLA, DGLA, ARA, and DHA in all subjects at
respective time points (n 39). Because of multiple compari-
sons, values of P,0·001 are considered significant, while
values of P,0·01 are considered a strong trend. Significant
positive correlations (P,0·001, r . 0·70) were observed
between TL and CE as well as between TL and PL fatty
acid changes (Table 7). Correlations between TL and TAG
fatty acid changes were significant and positive for GLA,
DGLA, and DHA (r . 0·58). Strong positive trends
(P,0·01) were observed for ARA changes after 4 and 8
weeks between TL and TAG (r . 0·43).
Discussion
The objective of this study was to investigate the effects of a
FSO/EPO blend on plasma fatty acid composition in healthy,
non-pregnant women. Previous studies had shown that sup-
plementation with DHA alone increased plasma lipid concen-
trations of DHA and (in most studies) EPA, but decreased
GLA, DGLA, and ARA concentrations16–23. Supplementation
with GLA on the other hand increased plasma concentrations
of DGLA as well as (in most studies) ARA and GLA levels,
Table 5. Fatty acid composition of plasma phospholipids (g/100 g total fatty acids)
FSO/EPO (n 19) Placebo (n 20)
Overall effect of treatment
Fatty acid Time (week) Mean SEM Mean SEM P *
18 : 3n-6† 0 0·096 0·006 0·104 0·011
4 0·126‡ 0·007 0·089 0·006
0·001
6 0·105 0·007 0·097 0·007
8 0·126‡ 0·008 0·089 0·009
20 : 3n-6 0 3·50 0·13 3·04 0·13
4 3·89‡ 0·22 3·09 0·16
0·015
6 3·77‡ 0·17 3·09 0·16
8 3·98‡ 0·21 2·98 0·14
20 : 4n-6† 0 9·16 0·36 9·61 0·24
4 8·73 0·33 9·46 0·26
0·844
6 8·88 0·47 9·03‡ 0·24
8 8·65 0·40 8·90‡ 0·20
22 : 6n-3† 0 3·34 0·13 3·09 0·15
4 4·90‡ 0·17 3·30 0·23
,0·001
6 5·08‡ 0·17 3·19 0·20
8 4·99‡ 0·14 3·23 0·22
FSO/EPO, fish oil and evening primrose oil blend.
* The overall effect of treatment on fatty acid composition was determined using the General Linear Model for repeated
measures corrected for fatty acid concentrations at baseline.
† Data were transformed before statistical analyses.
‡ Significantly different from baseline values (Bonferroni-Holm adjusted significances48).
Table 6. Fatty acid composition of plasma TAG (g/100 g total fatty acids)
FSO/EPO (n 19) Placebo (n 20)
Overall effect of treatment
Fatty acid Time (week) Mean SEM Mean SEM P *
18 : 3n-6† 0 0·301 0·034 0·362 0·045
4 0·442‡ 0·038 0·264 0·025
,0·001
6 0·406‡ 0·026 0·316 0·034
8 0·409‡ 0·041 0·311 0·049
20 : 3n-6 0 0·301 0·018 0·278 0·017
4 0·400‡ 0·025 0·268 0·021
,0·001
6 0·376‡ 0·018 0·274 0·013
8 0·378‡ 0·027 0·258 0·013
20 : 4n-6† 0 1·26 0·13 1·16 0·07
4 1·47‡ 0·11 1·14 0·08
0·001
6 1·39 0·11 1·16 0·10
8 1·37 0·11 1·09 0·08
22 : 6n-3† 0 0·682 0·078 0·490 0·040
4 1·500‡ 0·130 0·629 0·102
,0·001
6 1·491‡ 0·115 0·582 0·054
8 1·422‡ 0·099 0·590 0·091
FSO/EPO, fish oil and evening primrose oil blend.
* The overall effect of treatment on fatty acid composition was determined using the General Linear Model for repeated
measures corrected for fatty acid concentrations at baseline.
† Data were transformed before statistical analyses.
‡ Significantly different from baseline values (Bonferroni-Holm adjusted significances48).
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but did not affect DHA levels38–43. We hypothesised that the
tested n-3 LCPUFA–GLA mixture would result in an increase
of plasma DHA, GLA, and DGLA levels without impairing
ARA status.
This study showed that 8 weeks of supplementation with
FSO/EPO (456mg DHA, 72mg EPA, and 353mg GLA/d,
n-3 LCPUFA:GLA ratio 1 : 0·67) increased the proportions
of GLA and its elongation product DGLA in plasma TL and
in all measured plasma lipid fractions (CE, PL, and TAG)
compared to baseline, suggesting that at least some of the
GLA is elongated before incorporation into PL, CE or TAG.
These observations are consistent with those of Laidlaw &
Holub49, who found significant increases from baseline in
the proportions of GLA and DGLA (measured in plasma
PL) in healthy women given 4 g EPA þ DHA plus 2 g or
4 g GLA, respectively, for 4 weeks; no GLA and DGLA
changes could be observed in this study when the ratio of
n-3 LCPUFA to GLA was 4 g : 1 g. Miles et al.40 observed
increases in the proportion of GLA in plasma TAG and CE,
but not in PL, after supplementation with 1·1 g EPA, 0·5 g
DHA, and 1 g GLA/d (n-3 LCPUFA:GLA ratio1 : 0·625).
Other studies supplementing n-3 LCPUFA and GLA (in a
ratio from 1 : 0·33 to 1 : 1·14, absolute GLA amounts ranged
between 320mg and 3 g /d) could not detect any changes in
absolute GLA and DGLA amounts in plasma TL or in relative
concentrations of plasma PL41,42,50,51. The inconsistent effects
of combined n-3 LCPUFA and GLA supplementation on
plasma GLA and DGLA might be caused by the fact that
different absolute GLA amounts or different n-3 LCPUFA:
GLA ratios were studied: Laidlaw & Holub49 observed
increasing DGLA values with increasing amounts of GLA
and constant EPA þ DHA dosages. Concerning the changes
in GLA levels, an additional reason for the variable findings
in the literature may be the lipid fraction studied; as demon-
strated by several investigators40,52, GLA is mainly found in
CE and TAG, but hardly in PL (,0·1wt%). Thus, GLA
changes in plasma PL might be more difficult to detect,
because reproducibility and accuracy of the method might
be worse for small analyte concentrations. The power of a
study to detect an existent difference depends also on the
dimension of the difference, the variation of the parameter
in the tested population as well as on the sample size.
In the present study, the proportion of ARA increased in
plasma TAG, whereas ARA levels did not change significantly
in plasma TL, CE, and PL. Other investigators reported
decreased49,50 or unchanged40,41,51 plasma ARA levels in TL
or PL with n-3 LCPUFA–GLA supplementation compared
to baseline. The inconsistent effects on ARA levels may
relate on the one hand to the lipid fraction studied, on the
other hand to differences in the absolute GLA, ARA, and
EPA contents or to the EPA:GLA ratios of the supplements
used. EPA and DGLA compete with ARA for esterification
into phospholipids and furthermore, the (n-3) fatty acid pro-
duct of the D5-desaturase reaction, EPA, attenuates the con-
version of (GLA-derived) DGLA to ARA41,53. In the current
Fig. 1. Percentage fatty acid changes from baseline values after 8 weeks of intervention. Values are means with standard deviations indicated by vertical bars.
Percentage changes from baseline values were significantly different between FSO/EPO (n 19, V) and placebo (n 20, †) treatments with *P,0·05; †P,0·01;
‡P,0·001. ARA, arachidonic acid; CE, cholesterol esters; DGLA, dihomo-g-linolenic acid; GLA, g-linolenic acid; PL, phospholipids; TL, total lipids.
Table 7. Spearman r correlations between plasma total lipid and lipid
fraction percentage fatty acid changes (% of basal values, n 39)
Percentage fatty acid changes (% of basal value)
TL–CE TL–PL TL–TAG
r P * r P * r P *
18 : 3 n-6
week 4 0·961 ,0·001 0·872 ,0·001 0·815 ,0·001
week 6 0·953 ,0·001 0·843 ,0·001 0·586 ,0·001
week 8 0·949 ,0·001 0·846 ,0·001 0·757 ,0·001
20 : 3 n-6
week 4 0·813 ,0·001 0·916 ,0·001 0·665 ,0·001
week 6 0·839 ,0·001 0·966 ,0·001 0·698 ,0·001
week 8 0·896 ,0·001 0·941 ,0·001 0·776 ,0·001
20 : 4 n-6
week 4 0·767 ,0·001 0·736 ,0·001 0·436 0·006
week 6 0·842 ,0·001 0·861 ,0·001 0·374 0·019
week 8 0·706 ,0·001 0·826 ,0·001 0·461 0·003
22 : 6 n-3
week 4 0·933 ,0·001 0·948 ,0·001 0·893 ,0·001
week 6 0·948 ,0·001 0·975 ,0·001 0·879 ,0·001
week 8 0·957 ,0·001 0·971 ,0·001 0·923 ,0·001
CE, cholesterol ester; PL, phospholipids; TL, total lipids.
* Because of multiple comparisons values of P,0·001 are considered significant;
Values of P,0·01 are considered a strong trend.
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study, the GLA amount of the supplement appeared to be ade-
quate (n-3 LCPUFA:GLA 1 : 0·67; EPA:GLA 1 : 4·8) to avoid
a decrease of ARA levels in plasma, which is often observed
with n-3 LCPUFA supplementation.
FSO/EPO supplementation increased the proportions of
DHA in all investigated plasma lipid domains. Consistent
with our results, other studies supplementing n-3 LCPUFA
combined with GLA also observed increased DHA levels in
plasma TL and PL40–42,49–51.
The present study also serves to compare the intervention
effect on plasma fatty acid composition and the variation of
fatty acid changes between the different lipid domains. This
information is valuable for the planning of future intervention
studies with plasma fatty acid changes as outcome variables.
The maximal effects on GLA, DGLA, and DHA content were
already reached after 4 – 6 weeks of FSO/EPO supplementation
in all studied plasma lipids; therefore, the intervention period of
8 weeks seems to be adequate and could possibly be reduced to 6
weeks in future studies. Regarding all subjects at study entry
(n 40), highest GLA contents were found in CE, TAG, and TL
(medians: 0·85, 0·31 and 0·37wt% respectively), but GLA per-
centages were very low in phospholipids (,0·1wt%) as already
demonstrated by several investigators40,52. DGLA, ARA, and
DHA concentrations, on the other hand, were highest in
plasma PL (medians: 3·43, 9·34 and 3·09wt%, respectively)
and considerably lower in CE and TAG. As relative fatty acid
changes (in % of basal values) for GLA, DGLA, ARA, and
DHA were significantly and positively correlated between
plasma TL and lipid fractions or showed strong positive trends
(exception ARA levels between TL and TAG at week 6), fatty
acid analyses might be limited to plasma TL, provided that the
subjects are healthy (no dyslipidaemia), non-pregnant and
fasted (because these latter conditions cause general lipidaemia
or NEFA increase, respectively). In our subjects, the ratio of PL,
CE or TAG to plasma TL fatty acids (C14 – C24, mg/l:mg/l)
changed only negligibly between weeks 0, 4, 6, and 8 (PL:TL
44·7–45·0%, CE:TL 26·0–26·7%, TAG:TL 19·5–20·0%,
means, P.0·05 between the four time points, Friedman test);
this finding is probably an important condition for the strong cor-
relations between fatty acids of plasma TL and lipid fractions.
These strong correlations leave the required group size as the
main determinant of the decision on which lipid domain to
measure for checking the biochemical effects of fatty acid sup-
plementation studies.
Based on fatty acid levels, responses (week 8 minus week 0)
and variations observed in this study, sample size determinations
for unpaired t tests (using BIAS forWindows, version 8.1, Epsi-
lon-Verlag, Hochheim-Darmstadt, Germany) indicate that for a
minimal GLA increase of 20% from basal values caused by
FSO/EPO supplementation to be detected as significantly differ-
ent compared to placebo changes (assumedmean change 0%) at
a ¼ 5%andb ¼ 20%, about 62, 63, 104 and 172 volunteers per
group are needed when determining GLA in plasma TL, CE, PL
and TAG, respectively. For a DGLA increase of 20% to be
detected as significantly different from placebo changes, about
14, 11, 15, and 41 volunteers per group are needed when deter-
miningDGLA in plasmaTL, CE, PL andTAG, respectively. For
a DHA increase of 20% to be detected as significantly different
compared with placebo changes, about 28, 31, 27, and 158 vol-
unteers per group are needed when determining DHA in plasma
TL, CE, PL and TAG, respectively. Thus, plasma TL and CE
seem to be most suitable to detect between-group differences
in GLA changes, while plasma TL, CE, and PL might be simi-
larly suitable compartments to detect differences in plasma
DGLA or DHA changes.
To sumup, plasmaTL as biomarkers for n-6 and n-3 fatty acid
status have the following positive attributes: the tested n-6 and
n-3 fatty acids (GLA, DGLA, ARA, and DHA) are present in
adequate amounts in plasma TL and the fatty acid composition
responds to increasing EFA–LCPUFA intakes and is correlated
with fatty acid levels in plasma PL, CE and TAG. In addition,
plasmaTLoffer, compared to plasmaPL andTAG, a higher stat-
istical power to detect significant and clinically meaningful
differences in GLA, DGLA and DHA changes compared with
a placebo group. Statistical power of plasmaCE analysis is simi-
lar to plasma TL analysis. Finally, the analyses of plasma TL
fatty acids are less demanding than lipid fraction analyses, and
the required plasma volume is smaller. A disadvantage is that
the fatty acid composition in plasma TL is influenced by the
fatty acid composition of the last meal and the scheduling of
the blood sampling relative to the last meal. Consequently,
blood should be sampled in the fasting state. Thismay be proble-
matic in pregnant women and is not acceptable in neonates. For
these subjects, plasma CEmight be the best choice to investigate
GLA, DGLA and DHA changes.
In conclusion, the fatty acid supplement is well tolerated and
appears safe. FSO/EPO intake resulted in the anticipated
increase of plasma GLA, DGLA, and DHA levels without
impairing the ARA status. These data provide a basis for testing
FSO/EPOnot only in respect to biochemical changes in pregnant
women and their neonates, but also to evaluate its effects on
maternal mood, cognition, and selective attention, as well as
on visual and cognitive development of the infants, early mar-
kers of allergy risk and prevention of obesity, insulin resistance,
hypertriacylglycerolaemia or other chronic diseases in later life.
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